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clinicopathological backgrounds of the tumours than the 
established and widely used MSI grades, MSI-H and MSI-
L. Type B MSI widely correlated with family history of 
hereditary non-polyposis colorectal cancer-associated can-
cers, whereas MSI-H only did with that of colorectal can-
cer. Furthermore, mutation in the KRAS oncogene, which 
has been regarded as generally infrequent in microsatellite-
unstable tumours, was clearly associated with Type A MSI.
Conclusions Our observations may suggest a biologi-
cal relevance and a potential utility of the modal classifi-
cation of MSI and, furthermore, added complexities to 
genomic instability underlying tumourigenesis in human 
endometrium.
Keywords Microsatellite instability · DNA mismatch 
repair · Endometrial cancer · KRAS mutation · Familial 
predisposition
Background
Somatic instability of repetitive DNA sequences compris-
ing minimal reiterative motifs, i.e. microsatellite instabil-
ity (MSI), has initially been reported in tumours arising in 
Lynch syndrome [LS, alias hereditary non-polyposis colo-
rectal cancer (HNPCC)] patients (Aaltonen et al. 1993), 
in which germline mutations in the genes functioning in 
DNA mismatch repair (MMR) are often found. MMR is an 
important cellular system that counteracts replication errors 
caused by DNA polymerases and, consequently, guarantees 
the high fidelity of DNA replication on the genome. Repeti-
tive sequences such as microsatellites are particularly prone 
to replication errors, because DNA polymerases often slip 
on the repetitive sequences, and strand misalignment is 
formed. These replication errors, if uncorrected, are fixed 
Abstract 
Purpose Microsatellite instability (MSI) in human endo-
metrial cancer (EC) was analysed using a unique fluores-
cent technique. MSI is associated with various human neo-
plasms. However, the reported frequency of MSI differs 
widely in each malignancy. Methodological difficulties 
have in fact been pointed out in its assay techniques.
Methods We previously established a sensitive fluorescent 
technique in which the major methodological problems are 
overcome. Application of this technique has revealed two 
distinct modes of microsatellite alterations, i.e. Type A and 
Type B. In the present study, we have applied this tech-
nique to 94 ECs.
Results Significant microsatellite alterations were 
observed in 38 (40.4 %) tumours of the panel. The two 
modes, Type A and Type B, were indeed observed in 
this malignancy. More importantly, we found that the 
modes more closely correlated with the molecular and 
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during subsequent replication as addition or deletion of one 
or more repeat units. Thus, the phenomenon of MSI has 
been considered to reflect MMR deficiency in tumour cells. 
As MSI is frequently observed in various human neoplasms 
(Arzimanoglou et al. 1998), analyses of MSI have been 
prevalent in the fields of oncology or pathology. Numerous 
studies have been done on a wide variety of human malig-
nancies and addressed the characteristics of MSI+ tumours.
The reported frequency for MSI+ tumours in each 
malignancy, however, differs widely in the literature. 
In order to manage the confusion raised in the field, the 
National Cancer Institute (NCI) sponsored the workshop, 
‘Microsatellite Instability and RER Phenotypes in Cancer 
Detection and Familial Predisposition’ (Boland et al. 1998) 
in 1997, which concluded that the variety of microsatel-
lites used was a major cause of discrepancies among data 
from various laboratories and, consequently, recommended 
a panel of five microsatellites as a ‘working reference 
panel’. In addition, the NCI workshop recommended that 
the MSI+ phenotype should be classified into two different 
grades, i.e. MSI-H (high) and MSI-L (low), according to 
the frequencies of changes in a defined set of microsatel-
lite markers. However, the diversity of data in the literature 
has not improved since then. Analysis of MSI is now com-
monplace, but several methodological problems have in 
fact been pointed out in the conventional assay techniques 
(Maehara et al. 2001) and may also account for the vari-
ability in results. We previously established a unique fluo-
rescent technique designated as high-resolution fluorescent 
microsatellite analysis (HRFMA), in which products of 
polymerase chain reaction (PCR) are precisely and quan-
titatively resolved (Oda et al. 1997). In this technique, (a) 
electrophoretic profiles of microsatellites PCR products are 
simplified enzymatically or by primer sequence modifica-
tions, (b) each DNA fragment is detected quantitatively by 
use of an automated DNA sequencer, and (c) two differ-
ently labelled PCR products derived from tumour (red) and 
the corresponding normal tissues (green) are co-electro-
phoresed (see Fig. 1), in order to exclude migration errors. 
Application of this technique has revealed a number of 
previously unrecognised aspects of MSI in human cancer. 
In particular, we found two qualitatively distinct patterns 
of microsatellite alterations, i.e. Type A and Type B (Oda 
et al. 2005). Although this distinction has not widely been 
discussed, our previous data suggest that different molec-
ular abnormalities may underlie these two modes of MSI 
(Oda et al. 2005). It is widely known that tumours exhibit-
ing the MSI-H phenotype form a distinct entity with unique 
clinicopathological and molecular characteristics, particu-
larly in colorectal cancer (Jass et al. 2002), and accord-
ingly, two mutually exclusive pathways are hypothesised in 
colorectal tumourigenesis (Lengauer et al. 1998). Several 
reports, however, suggest that this distinction might be an 
oversimplification (Goel et al. 2003; Hawkins et al. 2001; 
Jass et al. 2002; Young et al. 2001). Attention has been 
drawn to the classification of the MSI phenotypes in human 
cancer.
Microsatellite alterations are most frequently observed 
in tumours occurring in LS kindred. More than 90 % of LS 
tumours are MSI+ (Liu et al. 1996). In the sporadic setting, 
endometrial carcinoma (EC) is one of the most microsat-
ellite-unstable human neoplasms. EC indeed occurs in LS 
patients and is the second most frequent malignancy in LS. 
Numerous data have been collected on the microsatellite 
alterations observed in EC, and similarly to colorectal can-
cer, the MSI-H phenotype is now regarded as characteristic 
of a subset of ECs (Yeramian et al. 2013). However, also 
in EC, the data accumulated in the literature are diverse 
(see Discussion). In addition, the Type A/B classification 
has not been applied in assessing MSI in ECs. Using our 
unique dual-colour fluorescent technique (Oda et al. 1997), 
we analysed microsatellite alterations in detail in a rela-
tively large panel of tumours from EC patients and found 
that the two modes of MSI, i.e. Type A and Type B, are 
indeed observed in this malignancy. More importantly, the 
modes more closely correlated with the clinicopathological 
and molecular backgrounds of the tumours than the MSI-
H/L grades, which suggests that, in addition to the estab-
lished classification according to the frequencies of micro-
satellite changes, the modal classification may also be of 
potential use. Here, we report the modal variety of MSI in 
human endometrial cancer and its biological significance.
Methods
Patients and tissue specimens
Samples of cancer and the corresponding normal tissues 
were collected from consecutive 94 EC patients who under-
went surgery in Gynaecology Division of National Kyushu 
Cancer Center (NKCC) from 1997 to 2003. According 
to histopathological diagnosis, non-endometrioid-type 
tumours were excluded from the patient panel. This panel 
includes one LS patient who fulfilled Amsterdam Criteria 
II (Vasen et al. 1999). Specimens, taken immediately after 
resection, were placed in liquid nitrogen, and then stored at 
−80 °C.
DNA extraction
Tissue specimens were lysed in digestion buffer (10 mM 
Tris-Cl pH 8.0, 0.1 M EDTA pH 8.0, 0.5 % SDS, 20 µg/
ml pancreatic RNase). After treatment with proteinase K 
and extraction with phenol, DNA was precipitated with 
ethanol, then dissolved in 1X TE (10 mM Tris-Cl pH 7.5, 
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1 mM EDTA). The concentration of DNA was determined 
by OD260 using a spectrophotometer. The quality of DNA 
was checked by agarose gel electrophoresis.
Microsatellite instability
Microsatellite analysis using fluorescence-labelled prim-
ers and an automated DNA sequencer has been described 
in detail (Oda et al. 1997). Briefly, five selected human 
dinucleotide microsatellites, D2S123, D5S107, D10S197, 
D11S904 and D13S175 (Oki et al. 1999), were ampli-
fied by polymerase chain reaction (PCR). Mononucleo-
tide microsatellites were not used in order to exclude the 
influence of the terminal deoxynucleotidyl transferase 
(TDT) activity of thermostable DNA polymerases (see 
Discussion). Forward primers were labelled with the fluo-
rescent compound, 6-FAM (6-carboxyfluorescein) or HEX 
(6-carboxy-2′, 4′, 7′, 4, 7, hexachloro-fluorescein). TaKaRa 
Taq (Takara Bio Inc., Otsu, Japan) was used as a thermo-
stable polymerase. To compare the electrophoretic profiles 
between two samples, 6-FAM-labelled products and HEX-
labelled products were mixed and co-electrophoresed in 
the ABI310 sequencer (Life Technologies, Carlsbad, CA, 
USA). The data were processed using the GeneScan soft-
ware (Life Technologies).
DNA sequencing
All the exons and exon-intron junctions of MSH2 and 
MLH1 were amplified by PCR using Taq polymerase with 
Fig. 1  Microsatellite alterations 
observed in human endome-
trial cancer. Using genomic 
DNA samples prepared from 
tumour and the corresponding 
normal tissues, microsatel-
lite sequences, indicated at 
the right top of each panel, 
were independently amplified 
by PCR with differentially 
labelled primers, then mixed 
and co-electrophoresed in an 
automated DNA sequencer. 
Representative results are 
shown and detected microsatel-
lite alterations are indicated by 
arrows: red lines cancer, green 
lines normal tissues, a negative 
cases, b Type A MSI, c Type 
B MSI, d cases suspected for 
LOH. Data in cases of separate 
and inseparable heterozygous 
microsatellites are shown in left 
and right columns, respectively. 
Patient codes corresponding to 
those used in Table 1 are also 
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3′ exonuclease activity, TaKaRa Ex Taq™ (Takara Bio Inc.). 
The sequencing strategy used is the same as the one reported 
by Kolodner Kolodner et al. (1994, 1995), except that the 
sequence complementary for M13 universal primer was 
deleted from each of the primer sequences, and that one-step 
PCR was employed. PCR products were used as a template for 
cycle sequencing reactions using BigDye Terminator Cycle 
Sequencing Kit (Life Technologies). Mutations found in one 
PCR product were verified by reverse sequencing and finally 
confirmed in two independently amplified PCR products.
The 107-bp region in the exon 2 of the KRAS gene 
that encompasses the mutation hotspots, codons 12 and 
13, was amplified by PCR using ‘c-Ki-ras/12 primer set’ 
(‘c-Ki-ras/12 forward’, 5′-GACTGAATATAAACTT-
GTGG; ‘c-Ki-ras/12 reverse’, 5′-CTATTGTTGGATCAT-
ATTCG) (Takara Bio Inc.) and TaKaRa Ex Taq™ (Takara 
Bio Inc.). PCR products were directly used as a template 
for cycle sequencing reactions using BigDye termina-
tor cycle sequencing kit (Life Technologies). The reverse 
primer, ‘c-Ki-ras/12 reverse’, was used for cycle sequenc-
ing reactions. Mutations found in one PCR product were 
verified by sequencing using our original inner primer that 
is 5′-adjacent to ‘c-Ki-ras/12 reverse’, KRAS2EX2R2 
(5′-TCCACAAAATGATTCTGAATTAGC), and finally 
confirmed in three independently amplified PCR products.
Immunohistochemistry
Tissue specimens were fixed in buffered 10 % formaldehyde 
and embedded in paraffin. Prior to the assay, the specimens 
were sectioned at 4 µm and deparaffinised using xylene. 
Antigen retrieval was done by heating the sections in cit-
rate buffer. Endogenous peroxidase activity was blocked 
by incubation in 3.0 % H2O2. Non-specific protein binding 
was inhibited by incubation in 10 % normal goat serum. 
The sections were reacted with an adequately diluted anti-
MSH2 mouse monoclonal antibody, clone GB12 (Calbio-
chem Novabiochem-Oncogen, Oncogen Research Products, 
Cambridge, MA, USA), or an anti-MLH1 antibody, clone 
14 (Calbiochem Novabiochem-Oncogen, Oncogen Research 
Products) at 4 °C overnight. The sections were next reacted 
with biotinylated goat anti-mouse IgG antibody (Dako Den-
mark A/S, Glostrup, Denmark) and then with peroxidase-
labelled streptavidin (Dako Denmark A/S). Finally, the 
sections were incubated with diaminobenzidine and H2O2. 
Counterstaining was done using Mayer’s haematoxylin. 
Negative control experiments were also performed by replac-
ing the primary antibodies with a non-specific mouse IgG.
Statistical analysis
Fisher’s exact probability test was used in all the statistical 
analyses.
Results
High‑resolution fluorescent microsatellite analysis 
(HRFMA) reveals the modal variety of microsatellite 
instability in endometrial cancer
In MSI+ tumours, changes in microsatellite lengths are 
sometimes minor and as small as loss or gain of a sin-
gle repeat unit, and cells carrying microsatellite changes 
are not always major in a given sample. However, using 
HRFMA, such minor and subtle alterations are sensi-
tively and quantitatively detected, and results are highly 
reproducible in several independent experiments. We have 
applied this technique for MSI analyses in a panel of 94 
ECs, in order to analyse microsatellite alterations in this 
malignancy in detail. The system sensitively detected vari-
ous microsatellite changes. Examples are shown in Fig. 1. 
The basic electrophoretic profile of PCR-amplified dinu-
cleotide microsatellite sequences is a cluster of three two 
base-pitched peaks. In human populations, microsatellites 
are highly polymorphic and, therefore, the parental alleles 
are different in length in many cases. In such cases, two 
peak clusters are separate (Fig. 1a, left) or, sometimes, 
partially overlap (Fig. 1a, right). Abnormal microsatel-
lite length changes in cancer cells are detected as appear-
ance of new peaks or changes in the peak heights in the 
electrophoretic profiles (Fig. 1, red lines). In the analyses 
of ECs, microsatellite length alterations were relatively 
small and within 6-bp in some cases (Fig. 1b). In the other, 
more drastic changes involving longer than 6-bp were also 
observed (Fig. 1c). We have designated the former type of 
microsatellite alterations as Type A and the latter as Type 
B in our previous observations (Oda et al. 2005). As Type 
B alterations involve large and, sometimes, discontinu-
ous differences in microsatellite length, it can appear as if 
‘new’ alleles, in addition to the parental alleles, are present 
(Fig. 1c). In EC, this type of microsatellite changes were 
frequently observed (Table 1), which is in clear contrast 
to other malignancies including colorectal cancer (Ikeda 
et al. 2001). In DNA fragment analyses using an automated 
sequencer, loss of heterozygosity (LOH) is also detectable 
(Fig. 1d, left), but some patterns of peak clusters are theo-
retically indistinguishable between MSI and LOH (Fujii 
et al. 2009) (Fig. 1d, right). These cases are indicated as 
‘LOH’’ in Table 1. Despite minimised false positives, sig-
nificant microsatellite alterations were observed in a con-
siderable number of the subjects of the panel, and, conse-
quently, the frequency of MSI+ tumours has been estimated 
to be 40.4% (38/94). According to the established NCI 
guideline, the MSI+ ECs were also classified into MSI-H 
and MSI-L (Table 1). The frequencies for MSI-H and 
MSI-L were 37.2 % (35/94) and 3.2 % (3/94), respectively. 
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Table 1  Microsatellite 
alterations observed n 94 
endometrioid endometrial 
cancer patients
Patient code Microsatellite MSI A/B MSI-H/L
D2S D5S D10S D11S D13S
1 B B B – B B H
2 B B B A – Ba H
3 B B B A A B H
4 B B B A B B H
5 A B B A B B H
6 B A B – B B H
7 B B B A B B H
8 B B B A B B H
9 B A B – B B H
10 A A B A B B H
11 A B B – A B H
12b B B A A A B H
13 B A B – A B H
14 A B B – A B H
15 A B B A – B H
16 B A B A – B H
17 B – A – B B H
18 A B B A A B H
19 A A B A B B H
20 B A A – A B H
21 A A B A A B H
22 A A B A A B H
23 A A B A A B H
24 A B A A A B H
25 B A A A A B H
26 B A A A – B H
27 B A A – A B H
28 A A A – B B H
29 A A B – – B H
30 A B A – A B H
31 A A A – A A H
32 A A A A – A H
33 A A LOH’c A A A H
34 A – – A A A H
35 A – A – – A H
36 A – – – – A L
37 A – – LOH’ – A L
38 LOH A – – – A L
39 LOH’ – – – N S
40 – – – – LOH’ N S
41 – LOH’ LOH’ – – N S
42 – – – LOH’ – N S
43 LOH’ – – – – N S
44 LOH’ LOH’ – – LOH’ N S
45 – LOH’ – LOH – N S
46 – LOH – – LOH’ N S
47 – LOH LOH’ LOH LOH’ N S
48 LOH – LOH’ – – N S
49 – – LOH LOH LOH’ N S
50 LOH – LOH’ – – N S
51 LOH – LOH’ – – N S
52 LOH – – LOH LOH’ N S
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MSI microsatellite instability, A Type A MSI, B Type B MSI, H MSI-high, L MSI-low, IHC immunohisto-
chemistry, + expressed, − no change/not expressed, ND not done, LOH loss of heterozygosity
a Tumours are classified as Type B when Type B alterations are observed in at least one marker
b The patient fulfilled Amsterdam Criteria II (Vasen et al. 1999), and a deleterious mutation (I586delT) of 
MLH1 was found in the tumour. Sequence alterations were not detected in the other tumours
c Changes theoretically indistinguishable between MSI and LOH are indicated as ‘LOH’’ (see text)
Table 1  continued Patient code Microsatellite MSI A/B MSI-H/L
D2S D5S D10S D11S D13S
53 LOH – – – – N S
54 – LOH LOH – N S
55 – – LOH – LOH N S
56 – – – – LOH N S
57 – LOH – – N S
58 – – LOH LOH – N S
59 – – LOH – – N S
60 – LOH – – N S
61 – – – – – N S
62 – – – – – N S
63 – – – – – N S
64 – – – – – N S
65 – – – – – N S
66 – – – – – N S
67 – – – – – N S
68 – – – – – N S
69 – – – – – N S
70 – – – – – N S
71 – – – – – N S
72 – – – – – N S
73 – – – – – N S
74 – – – – – N S
75 – – – – – N S
76 – – – – – N S
77 – – – – – N S
78 – – – – – N S
79 – – – – – N S
80 – – – – – N S
81 – – – – – N S
82 – – – – – N S
83 – – – – – N S
84 – – – – – N S
85 – – – – – N S
86 – – – – – N S
87 – – – – – N S
88 – – – – – N S
89 – – – – – N S
90 – – – – – N S
91 – – – – – N S
92 – – – – – N S
93 – – – – – N S
94 – – – – – N S
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The relationships between MSI-H/L and Type A/B MSI are 
expressed in Table 2, which are highly parallel to the figure 
obtained in our previous observations of colorectal cancer 
(Ikeda et al. 2001). 
Type A/B MSI characterises endometrial carcinomas 
with unique clinicopathological and molecular 
backgrounds
We next examined whether the observed microsatellite-unsta-
ble phenotypes correlated with common clinicopathological 
variables of the tumours. In EC, the MSI+ phenotype, particu-
larly the MSI-H phenotype, has been reported to correlate with 
tumour grade, stage and patient survivals (see Supplementary 
Table). However, none of these parameters correlated with the 
MSI-H phenotype in this study (Table 3). Instead, we found a 
significant correlation with patient age and, more importantly, 
family history of colorectal cancer. This tendency was also 
confirmed in the Type A/B classification. The more important 
finding is that Type B MSI correlated not only with family his-
tory of colorectal cancer but also with that of ‘HNPCC-asso-
ciated cancers’ (Vasen et al. 1999) (Table 4), which frequently 
arise in LS patients and includes, in addition to colorectal can-
cer and EC, carcinomas in the stomach, pancreas, small intes-
tine, ovary and the biliary or urinary tracts and the specific 
types of tumours in  the brain and the skin. The MSI+ 
phenotype is observed in more than 90 % of LS tumours (Liu 
et al. 1996) and now regarded as a molecular hallmark of LS. 
The strong association between Type B MSI and HNPCC-
associated cancers may suggest that the Type B phenotype 
may better reflect the biological backgrounds of the tumours.
The MSI+ phenotype in EC has also been reported to 
correlate with various gene mutations or gene expression 
changes in cancer cells. We therefore tested whether Type 
A/B phenotypes correlated with these molecular abnor-
malities. The KRAS gene is one of the most frequently 
mutated oncogenes in various human malignancies and 
is indeed known to be mutated in EC. Several early stud-
ies have reported that KRAS mutation was significantly 
associated with the MSI+ phenotype (Duggan et al. 1994; 
Lagarda et al. 2001). We therefore sequenced the genomic 
region of the KRAS gene that encompasses the most fre-
quently mutated codons, i.e. codons 12 and 13, in the MSI+ 
tumours of our panel. KRAS mutation was found in five 
tumours. Intriguingly, KRAS mutation was more closely 
associated with Type A MSI than with MSI-H/L (Tables 5 
and 6). This finding is consistent with our previous obser-
vation that KRAS mutation was frequently found in Type A 
colorectal tumours (Zhao et al. 2008). KRAS mutation was 
also frequent in tumours without family history of malig-
nancies, although this tendency was not statistically signifi-
cant (p = 0.07, data not shown).
Table 2  Relationship between MSI-H/L and Type A/B MSI
p = 0.01
Type A Type B Subtotal
MSI-H 5 30 35
MSI-L 3 0 3
Subtotal 8 30 38
Table 3  Clinicopathological variables and the NCI classification of 
MSI in endometrial cancer
a Carcinomas in the colorectum, endometrium, ovary and stomach 
were scored as ‘HNPCC-associated cancers’ (Vasen et al. 1999). The 
other HNPCC-related tumours were not found in the patients’ kindred
MSI grade p value
MSI-L MSI-H MSS
Number of cases 3 35 56
Age
 ≤55 3 23 24 0.02
 ≥56 0 12 32
Stage
 1 2 24 39 0.79
 2 0 0 2
 3 1 9 14
 4 0 2 1
Grade
 1 0 14 23 0.45
 2 2 12 24
 3 1 9 9
Survival
 Alive 3 33 47 0.31
 Dead 0 2 9
Family history
 Any cancer
 Yes 1 22 30 0.54
 No 2 13 26
 Colorectal cancer
 Yes 1 7 3 0.03
 No 2 28 53
 Gastric cancer
 Yes 0 11 16 0.70
 No 3 24 40
 HNPCC-associated cancersa
 Yes 1 16 16 0.20
 No 2 19 40
Double cancer
 Yes 0 4 12 0.43
 No 3 31 44
Menopause
 Before 2 12 19 0.58
 After 1 23 37
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Expression of one of the essential MMR genes, MLH1, 
is known to be often lost in microsatellite-unstable ECs, 
primarily due to silencing by promoter methylation (Her-
man et al. 1998), and another essential MMR gene, MSH2, 
has also been reported to be expressed at low levels in 
some previous studies (Hardisson et al. 2003; Ju et al. 
2006; Peiro et al. 2002). Loss of expression of these essen-
tial MMR genes causes defective MMR in cells and, con-
sequently, leads to a destabilisation of microsatellites on 
the genome. Using immunohistochemistry, we examined 
expression of MSH2 and MLH1 proteins in the EC tissues 
of our panel. Although both antigens were not detected in 
several cases, we found that loss of MLH1 expression was 
observed in the majority of MSI+ tumours (22/36), whereas 
being significantly less frequent in microsatellite-stable 
tumours (4/51, p < 0.01). We further examined whether 
MLH1 silencing is more closely associated with any of the 
MSI subcategories. However, MLH1 expression loss was 
similarly frequent both in Type B and in MSI-H tumours, 
and therefore, the correlations were not significantly dif-
ferent between the two classifications (data not shown). 
Contrary to the results of the MLH1 immunohistochemis-
try, MSH2 expression loss was similarly infrequent both 
in MSI+ tumours and in those with stable microsatellites 
and, consequently, not associated with the MSI+ phenotype 
(data not shown).
Discussion
Numerous studies have been done on the microsatellite 
alterations observed in human ECs to date. Supplementary 
Table provides a summary of the literature. Studies of vari-
ous sizes have been conducted on various subjects of dif-
ferent histological subtypes and genetic backgrounds, and 
the reported frequency for MSI+ tumours varies from 10 
to 100 %, even if confined to the studies about endometri-
oid-type tumours in the sporadic setting. This variability in 
results may not be explicable merely from the variety of 
the subjects (Supplementary Table). As mentioned above, 
the reported frequency of MSI+ tumours in each malig-
nancy is indeed diverse in the literature, and this confusion 
in the field has continued ever since. The variety of targets 
for analysis, i.e. microsatellites, will also undoubtedly lead 
to the variability in results. Although the NCI workshop in 
1997 (Boland et al. 1998) recommended the ‘working ref-
erence panel’ comprising two mononucleotide and three 
dinucleotide microsatellites, various microsatellites, includ-
ing tetranucleotide microsatellites, have in fact been used 
in the field (see Supplementary Table). Moreover, the MSI 
frequency differs widely even within the studies using only 
mononucleotide and dinucleotide microsatellites (Supple-
mentary Table). We believe that, in addition to selection of 
Table 4  Clinicopathological variables and the MSI mode of MSI in 
endometrial cancer
a Carcinomas in the colorectum, endometrium, ovary and stomach 
were scored as ‘HNPCC-associated cancers’ (Vasen et al. 1999). The 
other HNPCC-related tumours were not found in the patients’ kindred
MSI mode p value
Type A Type B negative
Number of cases 8 30 56
Age
 <55 8 18 24 0.01
 >56 0 12 32
Stage
 1 5 21 39 0.76
 2 0 0 2
 3 3 7 14
 4 0 2 1
Grade
 1 2 12 23 0.65
 2 3 11 24
 3 3 7 9
Survival
 Alive 8 28 47 0.36
 Dead 0 2 9
Family history
 Any cancer
 Yes 3 20 30 0.26
 No 5 10 26
 Colorectal cancer
 Yes 1 7 3 0.04
 No 7 23 53
 Gastric cancer
 Yes 0 11 16 0.14
 No 8 19 40
 HNPCC-associated cancersa
 Yes 1 16 16 0.03
 No 7 14 40
Double cancer
 Yes 0 4 12 0.33
 No 8 26 44
Menopause
 Before 3 11 19 0.95
 After 5 19 37




 Mutant 1 4 5
 Wild type 2 31 33
 Subtotal 3 35 38
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targets for analysis, methodological problems at least partly 
account for the variability in results. Microsatellite length 
changes are sometimes as small as one or two base pairs in 
mononucleotide or dinucleotide microsatellites. Such small 
sequence alterations are not detectable in electrophoresis 
with significant migration errors, or under the influence of 
TDT activity of thermostable DNA polymerases such as 
Taq, which adds one additional base to PCR products in a 
sequence-dependent manner. In addition, cell populations 
carrying microsatellite alterations are not always predomi-
nant in a given sample. However, it is difficult to detect less 
abundant PCR products in an assay system using autora-
diography or silver staining, due to their nonlinear detec-
tion characteristics. We previously established a sensitive 
fluorescent technique in which all of these methodologi-
cal problems are overcome, and, in the present study, this 
technique was applied to address microsatellite altera-
tions in ECs. The overall frequency of MSI+ tumours was 
40 %, and several previous studies in the literature indeed 
reported similar frequencies (Furlan et al. 2006; Hardisson 
et al. 2003; Ohwada et al. 2002; Risinger et al. 2005) (Sup-
plementary Table).
The MSI+ phenotype is now connected to specific clin-
icopathological characteristics of tumours. In colorectal 
cancer, MSI+ tumours more frequently occur in the proxi-
mal colon and often exhibit characteristic histopathological 
features such as poor/signet ring cell differentiation, mucin 
secretion and lymphocyte infiltration (Jass et al. 2002), 
which are currently known as ‘MSI-H histology’ (Umar 
et al. 2004). Patient outcomes are in general believed to be 
more favourable in MSI+ colorectal carcinomas (Popat et al. 
2005). Accordingly, various clinicopathological features of 
tumours have been examined and are regarded as associ-
ated with the MSI+ phenotype in other human malignan-
cies. In EC, tumour histology, grade, location, stage and 
patient survivals have been reported (Supplementary Table). 
These parameters did not correlate with MSI in this study 
(Tables 3, 4). The clinical and histopathological phenotypes 
of tumours are determined by highly complicated systems. 
Their relationships to MSI may therefore be more complex 
than hitherto suspected. MSI is now regarded as a molecular 
hallmark of LS. Indeed, more than 90% of LS tumours are 
MSI+ (Liu et al. 1996), which implies that MSI well reflects 
molecular abnormalities underlying LS tumourigenesis. One 
important finding of the present study is that Type B MSI did 
significantly correlate with family history of HNPCC-asso-
ciated cancers, and that, on the other hand, MSI-H did not. 
This may be partly because the MSI-H phenotype sometimes 
includes Type A tumours (see Table 1) and inevitably tends 
to be heterogeneous in terms of the mode of microsatellite 
alterations. The tight connection between Type B MSI and 
LS tumourigenesis may suggest a biological importance of 
Type B alterations and, in addition, a potential advantage 
of the Type A/B classification. The MSI+ phenotype is also 
connected to various other genomic changes. Genetic insta-
bility observed in colorectal cancer has been regarded as 
deriving two mutually exclusive pathways, the chromosomal 
instability (CIN) pathway frequently associated with muta-
tions in various oncogenes or tumour suppressors such as 
TP53 and the microsatellite instability (MIN) pathway, in 
which TP53 mutations are rare and, instead, mutations are 
found in genes harbouring mononucleotide repeats within 
their ORFs (Schwartz et al. 1999). The frequency for KRAS 
mutations in MSI+ tumours has been controversial. Muta-
tions in the KRAS oncogene were initially regarded as infre-
quent in MSI+ tumours (Ionov et al. 1993; Salahshor et al. 
1999; Samowitz et al. 2001). However, in our previous study, 
we have shown that KRAS mutations are indeed observed in 
microsatellite-unstable tumours and, more importantly, are 
relatively frequent in tumours exhibiting Type A MSI (Zhao 
et al. 2008). Also in this study, KRAS mutation was closely 
associated with Type A instability. We have previously dem-
onstrated that Type A MSI is a direct consequence of defec-
tive MMR (Oda et al. 2005). A close association of Type 
A MSI with point mutations is highly consistent with the 
mutator phenotype in cells deficient in MMR (de Wind et al. 
1995; Reitmair et al. 1997). These observations may thus 
suggest that the modal classification is biologically relevant.
Using HRFMA, we confirmed that endometrioid-type 
EC is the most microsatellite-unstable neoplasm among the 
human malignancies thus far tested. In general, the frequen-
cies for MSI-H and MSI-L in colorectal cancer are 5–10 and 
10–20 %, respectively. The MSI-H phenotype is very rare in 
the other human neoplasms, and the most frequently observed 
microsatellite-unstable phenotypes are generally MSI-L. 
Nevertheless, the MSI-H phenotype predominates in our 
panel of ECs (Table 1). The frequency for MSI-H exceeded 
30%. The MSI-H phenotype is typical of LS (Liu et al. 1996). 
The high frequency of this phenotype in endometrioid-type 
EC may suggest that the majority of this subset of ECs arises 
from molecular backgrounds similar to those of LS or, in 
other words, via the MIN pathway. This hypothesis may be 
consistent with the consensus that mutations in TP53 are rela-
tively infrequent in endometrioid-type EC (Yeramian et al. 
2013), which are similarly regarded as rare in the MIN path-
way of colorectal cancer (Ionov et al. 1993; Salahshor et al. 
Table 6  KRAS mutation and Type A/B MSI
P = 0.05
Type A Type B Subtotal
KRAS
 Mutant 3 2 5
 Wild type 5 28 33
 Subtotal 8 30 38
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1999; Samowitz et al. 2001; Simms et al. 1998). Tumouri-
genesis in this pathway has not yet been well understood. 
Destabilisation of repetitive motifs may disrupt the genes 
harbouring repeats such as TGFBR2, IGF2R, BAX, CASP5 
etc (Schwartz et al. 1999). On the other hand, mutations in 
established oncogenes and tumour suppressor genes and 
chromosomal instability leading to LOH in tumour suppres-
sor loci are not hypothesised in the MIN pathway. Tumouri-
genesis without this classical model is still enigmatic. Type 
B MSI is observed in tumours exhibiting the MSI-H pheno-
type (Ikeda et al. 2001). This has been confirmed also in the 
present study (Table 2). Type B MSI indeed predominates 
in microsatellite-unstable ECs (Table 1). Our previous study 
suggests that defective MMR may be a promoting and, con-
sequently, highly coincidental (as typical in Lynch syndrome 
patients), but insufficient factor for Type B changes, whereas 
being necessary and sufficient for Type A instability. In other 
words, whereas Type A MSI is a direct consequence of defec-
tive MMR, molecular abnormalities in addition to MMR defi-
ciency may contribute to Type B alterations of microsatellites 
(Oda et al. 2005). Frequent Type B instability in endometrioid 
ECs suggests the possibility that this malignancy may provide 
a clue to Type B mechanisms and also serve as a good model 
for the MIN pathway tumourigenesis. Further analyses of the 
EC genome warrant particular attention.
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